Late Night Snack and Insulin Glargine

NCT ID: NCT02871180

Last Updated: 2016-08-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Twenty patient with Type 1 diabetes, using insulin glargine as basal insulin, participated in a prospective, controlled crossover trial comparing blood glucose profiles over two 24 h periods with and without a late night snack (a slice of rye bread, 20 g carbohydrates, at 10 p.m.), in randomized order. The main endpoint was the number of hypoglycemic episodes with a confirmed laboratory blood glucose ≤ 50 mg/dl between 10 p.m. and 8 p.m. the following day. Secondary endpoint was the blood glucose profile during this period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The order of studies (with and without a late night snack) was determined by randomization. Study-related procedures started at 6 p.m. (standard blood glucose profiles with determinations at 6, 8, and 10 p.m, at midnight, at 2, 4, 6:45, 8:45 a.m., and at noon and 2, 6, and 8 p.m. of the following day). At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten or no nutrients were consumed, as determined by the randomization protocol. After one day without study-related activities, the study was repeated with the complementary protocol (crossover design). Patients were instructed to use fast-acting insulin to correct hyperglycemia three times per day (before major meals) or to take in additional carbohydrate when symptomatic or chemical hypoglycemia was noted. They were asked not to perform strenuous exercise beyond their normal daily activities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Hypoglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With late night snack

At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.

Group Type OTHER

Late night snack

Intervention Type DIETARY_SUPPLEMENT

The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.

Without late night snack

Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..

Group Type OTHER

No late night snack

Intervention Type OTHER

Patient consumed no nutrients at late night.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Late night snack

The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.

Intervention Type DIETARY_SUPPLEMENT

No late night snack

Patient consumed no nutrients at late night.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes
* Basal insulin substitution with insulin glargine at least 3 month

Exclusion Criteria

* Severe disorders
* Severe and clinical significant gastroparesis
* History of pancreatitis or pancreatic cancer
* Severe Liver disorder (liver enzymes \> three times upper normal limit)
* Pregnancy
* Drug- or alcohol abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Diabeteszentrum Bad Lauterberg im Harz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael A. Nauck

Prof. Dr. med. Michael A. Nauck

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael A. Nauck, Prof.

Role: PRINCIPAL_INVESTIGATOR

St. Josef-Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Diabeteszentrum Bad Lauterberg

Bad Lauterberg im Harz, Lower Saxony, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Late night snack & Lantus

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glulisine + Lantus in Type I Patients
NCT00546702 COMPLETED PHASE3